Maze Therapeutics (NASDAQ:MAZE) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on shares of Maze Therapeutics (NASDAQ:MAZE) in a research note released on Tuesday morning,Benzinga reports. The firm issued an overweight rating and a $30.00 price objective on the stock.

Separately, Leerink Partners began coverage on Maze Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $28.00 price objective for the company. Three research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Maze Therapeutics currently has an average rating of “Buy” and an average target price of $25.67.

Maze Therapeutics Price Performance

NASDAQ MAZE opened at $12.72 on Tuesday. Maze Therapeutics has a 1-year low of $10.08 and a 1-year high of $17.00.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.